74645-03-7

Basic information

• Product Name: Butanoic acid, 2-amino-, methyl ester, (R)-
• CAS NO: 74645-03-7
• Molecular Formula: C5H11NO2
• Molecular Weight: 117.148
• Mol File: 74645-03-7.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 2-amino-, methyl ester, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-amino-, methyl ester, (R)-(74645-03-7)
• EPA Substance Registry System: Butanoic acid, 2-amino-, methyl ester, (R)-(74645-03-7)

Safety Data

• Hazardous Substances Data: 74645-03-7(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 34306-42-8 Boc-Abu 
• 7324-11-0 (S)-2-amino-butanamide 
• 75266-39-6 methyl (S)-2-<<(benzyloxy)carbonyl>amino>-4-(methylsulfinyl)butanoate 
• 2491-18-1 (S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride 
• 56762-93-7 methyl (S)-2-(benzyloxycarbonylamino)-4-methylmercaptobutanoate 
• 407578-43-2 (3S,6S)-3-isopropyl-6-ethylpiperazine-2,5-dione 
• 186581-53-3 diazomethane 
• 1492-24-6 L-2-aminobutyric acid 
• 75266-40-9 N-benzyloxycarbonyl-L-α-vinylglycine methyl ester 

Downstream Products

• 1313517-18-8 C₉H₁₇NO₃ 
• 1446420-34-3 C₈H₁₄F₃NO₂ 
• 947667-22-3 Methyl (2R)-2-(isopropylamino) butanoate 
• 946161-16-6 methyl (2R)-2-[(2-chloro-5-nitropyrimidin-4-yl)(propan-2-yl)amino]butanoate 
• 1313520-56-7 C₁₇H₂₅NO₃ 
• 755039-53-3 (R)-methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-amino)butanoate 
• 1036274-96-0 N-[(R)-1-methoxycarbonylpropyl]-(+/-)-2-cyano-2-fluoro-p-tolylacetamide 
• 755039-52-2 (R)-methyl 2-(cyclopentylamino)butanoate 
• 7324-11-0 (S)-2-amino-butanamide 
• 53726-14-0 (S)-2-amino-butanamide hydrochloride 

Relevant articles and documents

Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors

A series of novel tetrapeptidyl epoxyketone inhibitors of 20S proteasome was designed and synthesized. To fully understand the SAR, various groups at R1, R2, R3, R4 and R5 positions, including aromatic and aliphatic substituents were designed, synthesized and biologically assayed. Based on the enzymatic results, seven compounds were selected to evaluate their cellular activities and soluble compound 36 showed strong potency against human multiple myeloma (MM) cell lines. Microsomal stability results indicated that compound 36 was more stable in mice, rat and human microsomes than marketed carfilzomib. The in vivo activities of this compound were evaluated with the xenograft mice models of MM cell lines ARH77 and RPMI-8226 with luciferase expression and the T/C value of the two models were 49.5% and 37.6%, respectively. To evaluate the potential cardiovascular toxicity, inhibition of hERG ion channel in HEK293 cells by compound 36 and carfilzomib was carried out. The results indicated that 36 had no binding affinity for the hERG ion channel while carfilzomib could bind it with IC50 of 92.1 μM.

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.